A Preview Of Inovio Pharmaceuticals's Earnings
Inovio Pharmaceuticals INO is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Inovio Pharmaceuticals to report an earnings per share (EPS) of $-1.
INOVIO (INO) announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. In that ...
Shares of Inovio Pharmaceuticals Inc. INO slipped 1.94% to $5.56 Tuesday, on what proved to be an all-around mixed trading ...
MyChesCo on MSN3d
INOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14!INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) has announced that its financial results for the third quarter of 2024 will be released after the market closes on November ...
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
宾夕法尼亚州普利茅斯会议 - 专注于DNA疗法的生物技术公司INOVIO (NASDAQ:INO)发布了新的免疫学数据，表明其主要产品候选药物INO-3107可能会减少复发性呼吸道乳头状瘤病(RRP)患者的手术需求。这种疾病通常由人乳头状瘤病毒6型和11型(HPV-6和HPV-11)引起，会导致气道中良性肿瘤的生长，可能阻碍呼吸并对语言产生不利影响。 这些将在第36届国际乳头状瘤病毒会议上展示的数 ...
Publisher Astrolabe Games and solo developer Ino Kinwen have announced Rusty Winter, a 2.5D pixel art narrative-focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback